MARCELLUS CEPHAS: Open Payments
NPI 1134116007 · WHITESBORO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 38 payments from 11 companies in 2025. Trend: 2023 $566 · 2024 $418 · 2025 $736
Food & beverage: $624Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $244 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $181 |
| Alkermes, Inc. | 4 | $72 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| Lundbeck LLC | 2 | $45 |
| Janssen Pharmaceuticals, Inc | 1 | $37 |
| Indivior Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: CAPLYTA, UZEDY, ARISTADA, INGREZZA, REXULTI, AUSTEDO XR, INVEGA SUSTENNA, SUBLOCADE.
Industry payments across NY — which companies pay providers there.
